International legal practice Osborne Clarke has advised Lucid Group on its acquisition of leading consulting firm, Synetic Life Sciences ("Synetic"). The acquisition will further accelerate Lucid Group's mission to improve global health outcomes and help to confront today's healthcare challenges.
Founded in 2007, Lucid Group is a strategic healthcare consultancy committed to having a meaningful impact on health outcomes. Through its pioneering approach to healthcare strategies and communication, over the recent years, the company has evolved its capabilities and partnered with commercial and medical teams across the commercialisation journey of a medicine from early asset strategy to launch and beyond.
Synetic is a specialist management consulting firm focused on the life sciences industry including global biopharma companies, providers and investors. The company's deep sector expertise enables bespoke solution development that supports clients in designing, building and implementing fit for purpose operating models for commercial success.
The combined capabilities of Lucid Group and Synetic will provide clients with an end-to-end partnership across the development and commercialisation journey and deliver transformative solutions across clients' organisational needs and brand opportunities.
The Osborne Clarke Corporate team assisting Lucid Group was led by Partner Alistair Francis and included Associate Director Will Nicholson and Associate Harry Stewart. Additional support was provided by Associate Directors Rob Thomas (tax) and Lara Flynn (employment).
Lucid Group is a longstanding client, having most recently advised the management team on its partnership with new investor Intermediate Capital Group.
Osborne Clarke’s Corporate team is considered a go-to practice for many companies in the tech, marcoms and life sciences and healthcare sectors, working with global businesses to fast-growth start-ups and market challengers. The team advises at every stage of company development across all corporate issues, from equity and debt fundraisings to M&A, IPOs and JVs.